Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

Lars H Ehlers (Aalborg University) (Ophavsperson)
Mark Lamotte (Ophavsperson)
Mafalda C Ramos (Ophavsperson)
Susanne Sandgaard (Ophavsperson)
Pia Holmgaard (Ophavsperson)
Evan C. Frary (Ophavsperson)
Niels Ejskjær (Ophavsperson)

Datasæt

1 Tidsskriftartikel

1 resultater

2022
The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Ehlers, L. H., Lamotte, M., Ramos, M. C., Sandgaard, S., Holmgaard, P., Frary, E. C. & Ejskjær, N., jan. 2022, I: Journal of Comparative Effectiveness Research. 11, 1, s. 29-37 9 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Åben adgang
Fil
10 Citationer (Scopus)

167 Downloads (Pure)